Infinimmune and Grid Therapeutics formed a partnership to collaborate on identifying new antibody drug candidates for non-small cell lung cancer.
Elektrofi Inc., a biopharmaceutical formulation technology has entered a multi-target worldwide research collaboration and license agreement with Janssen Biotech Inc., a Johnson & Johnson company.
FDA approved Welireg (belzutifan) for patients with advanced renal cell carcinoma following a PD-1 or PD-L1 inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor.
FDA approved Iwilfin (eflornithine) to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy.
AnHeart Therapeutics and Foundation Medicine Inc. have entered a strategic collaboration for the development and regulatory approval of Foundation Medicine’s tissue- and liquid-based comprehensive genomic profiling tests, FoundationOne CDx and FoundationOne Liquid CDx, as companion diagnostics for AnHeart’s investigational next-generation ROS1 inhibitor, taletrectinib, in the United States.
Fuse Oncology and the University of Michigan formed a strategic collaboration focused on radiation oncology.
FDA approved Jaypirca (pirtobrutinib) for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor and a BCL-2 inhibitor.
FDA granted Fast Track Designation for Alpha1H for the treatment of non-muscle invasive bladder cancer. Alpha1H is sponsored by Hamlet BioPharma AB.
FDA approved Xtandi (enzalutamide) for non-metastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.
FDA has granted Breakthrough Therapy Designation to epcoritamab-bysp, an investigational T-cell engaging bispecific antibody administered subcutaneously, for relapsed or refractory follicular lymphoma.
